Editas Medicine (EDIT) Tops Q3 EPS by 2c

Editas Medicine (NASDAQ: EDIT) reported Q3 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $7.54 million versus the consensus estimate of $4.94 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• BofA says convenience store sales trail broader retail channels
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• iShares 20+ Year Treasury Bond ETF (TLT) call put ratio 1.3 calls to 1 put on 124K contracts